| Autor: |
Simon, Dagmar, Yousefi, Shida, Cazzaniga, Simone, Bürgler, Christina, Radonjic, Susanne, Houriet, Carine, Heidemeyer, Kristine, Klötgen, Hans‐Wilhelm, Kozlowski, Evelyne, Borradori, Luca, Simon, Hans‐Uwe |
| Předmět: |
|
| Zdroj: |
Allergy; Mar2020, Vol. 75 Issue 3, p669-672, 4p, 1 Chart, 1 Graph |
| Abstrakt: |
Enrolled patients presented with either a newly diagnosed disease or a relapse of BP.[1] The primary endpoint was the cumulative rate of relapse-free patients after initiating therapy. Despite the fact that mepolizumab did not significantly affect the clinical outcome, we found significantly lower peripheral blood eosinophil levels in patients treated with mepolizumab compared to patients receiving placebo (Table). (b) Since we could not estimate the effect of mepolizumab in these elderly patients in advance, for ethical reasons, we chose an add-on therapy, that is, mepolizumab or placebo were administered in addition to the standardized therapy with OCS. Even after therapy, eosinophils were detectable in the skin both in patients with and without relapse of BP. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text